{"Clinical Trial ID": "NCT00612560", "Intervention": ["INTERVENTION 1:", "Bras A - Flaxseed and Active Anastrazole", "25 mg of flax per day and 1 mg of anastrozole per day", "Anastrozole: 1 mg daily", "Flaxseed: 25 g per day", "INTERVENTION 2:", "Bras B - Flaxseeds", "Lin 25 mg daily and 1 placebo tablet daily", "Flaxseed: 25 g per day"], "Eligibility": ["Incorporation criteria:", "18 and 85 years of age", "A postmenopausal state defined as follows: no menstrual cycle in the last 12 months hysterectomy with bilateral hysterectomy oophorectomy with intact ovaries if age > 55 years", "Newly diagnosed with incident, primary, invasive, estrogen receptor positive clinical stage II or lower breast cancer", "ECOG performance status of 1 or less", "\u25a1 Willingness to comply with the guidelines and procedures of the study", "Willingness and ability to give informed consent", "\u2022 The usual consumption of soya must not exceed once a week and the desire to avoid whole soya foods or concentrated soya sources (soya milk, tofu, substitute meat products, meal replacement bars) during the intervention period", "\u2022 Willingness to avoid herbal and food supplements (excluding vitamins), aspirin and ibuprofen during the intervention period", "No concurrent treatment of neoadjuvant or chemotherapy", "The time between the pre-surgical visit and surgery must be at least 2 weeks", "No chemotherapy in the last 12 months", "- Exclusion criteria:", "Unable to read and write English", "Previous invasive breast cancer", "Insulin-dependent type I or II diabetes was diagnosed by a doctor.", "History of coagulopathy, thrombocytopenia or haemorrhagic disorder", "In progress (within the last 30 days) regular use (at least once a week) of reproductive hormone, tamoxifen, aromatase inhibitors or other inhibitors of estrogen, flax seeds or antibiotics", "Current chemotherapy or neoadjuvant chemotherapy", "Allergies with flaxseed, nuts or other seeds", "Renal dysfunction defined by creatinine > 1.5 mg/dl", "History of Crohns' disease, ulcerative colitis, irritable intestinal syndrome, celiac sprue, or other malabsorption, diverticulitis, diverticulosis, or other intestinal diagnosis which, in the opinion of the breast surgeon, would counter-indicate large doses of dietary fibre or hinder nutrient absorption", "\u2022 Routine, regular use (more than once a week) of prescription antihypertensive agents, including coumadine, heparin and medicinal products associated with heparin, clopidogrel bisulfate"], "Results": ["Performance measures:", "Estrogen receptor expression (ER-beta)", "Average percentage of cells expressing an estrogen receptor (ER-beta)", "Time limit: Biopsy/Week 1 and surgical resection/Week 2", "Results 1:", "Title of arm/group: Arm A - Flaxseed and active Anastrazole", "Description of the arm/group: 25 mg of flaxseed per day and 1 mg of anastrozole pill per day", "Anastrozole: 1 mg daily", "Flaxseed: 25 g per day", "Total number of participants analysed: 7", "Average (standard deviation)", "Unit of measure: percentage of biopsy cells: 7 participants", "- 67.1 (17.0)", "\u2022 Surgical resection: 7 participants", "45.7 (28.8)", "Results 2:", "Title of arm/group: arms B - linen", "Description of the arm/group: Lin 25 mg per day and 1 placebo tablet per day", "Flaxseed: 25 g per day", "Total number of participants analysed: 6", "Average (standard deviation)", "Unit of measurement: percentage of biopsy cells: 6 participants", "\u00b7 63.3 (10.3)", "\u2022 Surgical resection: 6 participants", "- 56.7 (23.4)"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/7 (0.00 per cent)", "- Breast haematoma 0/7 (0.00 %)", "Adverse Events 2:", "Total: 0/7 (0.00 per cent)", "- Breast haematoma 0/7 (0.00 %)"]}